1. Home
  2. CNEY vs INDP Comparison

CNEY vs INDP Comparison

Compare CNEY & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

N/A

Current Price

$0.74

Market Cap

5.9M

Sector

Industrials

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.75

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNEY
INDP
Founded
2009
2000
Country
China
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.2M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CNEY
INDP
Price
$0.74
$1.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
394.2K
50.9K
Earning Date
02-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.27
52 Week High
$3.25
$13.24

Technical Indicators

Market Signals
Indicator
CNEY
INDP
Relative Strength Index (RSI) 56.19 33.95
Support Level $0.54 $1.71
Resistance Level $0.80 $2.08
Average True Range (ATR) 0.08 0.28
MACD 0.01 -0.17
Stochastic Oscillator 84.11 0.59

Price Performance

Historical Comparison
CNEY
INDP

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: